Atrium Therapeutics, Inc. Common Stock (RNA) — Free Cash Flow Generation Index
Atrium Therapeutics, Inc. Common Stock (RNA) has a Free Cash Flow Generation Index of 0.95x as of December 2023. Free cash flow of $15.64 Million represents 1% of operating cash flow ($16.50 Million). Explore capital reinvestment ratio of Atrium Therapeutics, Inc. Common Stock to see what proportion of operating cash flow is directed to capital expenditures.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Atrium Therapeutics, Inc. Common Stock Free Cash Flow Generation Index (2019–2019)
Historical FCF Generation Index trend for Atrium Therapeutics, Inc. Common Stock across 1 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Atrium Therapeutics, Inc. Common Stock.
Annual Free Cash Flow Generation for Atrium Therapeutics, Inc. Common Stock (2019–2019)
Year-by-year Free Cash Flow Generation Index for Atrium Therapeutics, Inc. Common Stock. Check RNA cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
| Year | FCG Index | Free Cash Flow (USD) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2019 | 0.91x | $2.25 Million | $2.49 Million | $235.00K | — |